Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lonapegsomatropin - Ascendis Pharma

Next Previous
Drug Profile

Lonapegsomatropin - Ascendis Pharma

Alternative Names: ACP 001; ACP 011; Lonapegsomatropin-tcgd; SKYTROFA; TransCon growth hormone; TransCon hGH; TransCon PEG growth hormone; TransCon PEG hGH; TransCon PEG somatropin

Latest Information Update: 16 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ascendis Pharma
  • Developer Ascendis Pharma; Specialised Therapeutics Asia; VISEN Pharmaceuticals
  • Class Growth hormones; Hormonal replacements; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Human growth hormone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Somatotropin deficiency
  • New Molecular Entity No

Highest Development Phases

  • Marketed Somatotropin deficiency
  • Phase II Achondroplasia; Turner's syndrome

Most Recent Events

  • 09 Jun 2025 Efficacy and adverse events data from phase II clinical trials in Achondroplasia released by Ascendis Pharma
  • 29 May 2025 Registered for Somatotropin deficiency (In children, In adolescents) in Australia (SC)
  • 12 Jan 2025 Amicus Therapeutics plans to submit IND application for a basket trial in additional indications in Q3 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top